Tiziana Life Sciences Chief Medical Officer Dr. Matthew Davis joins Natalie Stoberman from the Proactive newsroom to explain how the company is pursuing the development of Intranasal Foralumab for the treatment of Long COVID.
Davis says Tiziana intends to enter into a three month Phase 2a placebo-controlled clinical trial to research how foralumab’s well-established role in de-activating microglia cells could treat or reduce the symptoms of Long COVID.